

Out of Hospital Management of COVID-19 Infection

Initial Evaluation

- Provide supportive care and symptom management as needed
- Provide education and resources to reduce risk of transmission to others
- Evaluate the need for higher level of care:
 - Persistent or progressive dyspnea
 - Oxygen saturation < 94%
 - Chest pain/tightness, dizziness, confusion, or mental status changes
- Determine if COVID-19 therapeutics are indicated
 - Therapeutics are indicated for those at **high risk of progressing to severe COVID-19**

Risk Factors for Severe COVID-19

Age


- The risk of severe outcomes 60 times higher in 65-74 year old patients than 18-29 year old patients and exponentially higher > 75 years old

Underlying Conditions

Asthma	Liver Disease
Cancer	Diabetes
Cerebrovascular Disease (Stroke)	Dementia
Kidney Disease	Obesity
COPD and other chronic lung diseases	

COVID-19 Therapeutics

- Long-term care patients often meet the above risk factors for severe disease and COVID-19 therapeutics **SHOULD** be considered even if initial symptoms are mild
- Providers should evaluate patients for the best therapeutic option
- COVID Therapeutics for Non-hospitalized patients
 - First Line: Paxlovid™ (ritonavir-nirmatrelvir) oral therapy
 - Second Line: Veklury® (remdesivir) intravenous therapy
 - Third Line: Lagevrio™ (molnupiravir) oral therapy



Information adapted from:

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/> Accessed 12/22/2022.

CDC Website: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html> Accessed 12/26/2023.



Qsource
www.Qsource.org

This material was prepared by Qsource, a/an Network of Quality Improvement and Innovation Contractors under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this document do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. 23.QIO.CLIN6.01.001